News | July 21, 1998

Fuisz and Novopharm to Share Technology

Two pharmaceutical companies, Fuisz Technologies Ltd.(Chantilly, VA) and Novopharm Limited (Toronto, Ontario), recently announced that they have agreed to licensing agreements under which Fuisz will develop controlled release versions of two undisclosed drug compounds using its Ceform CR (Controlled Release) technology for Novopharm. Neither company would comment on the specific drugs involved in the agreement.

The Ceform process allows for the quick manufacture of very small, perfectly round spheres—called microspheres—which contain active drug ingredients and other excipients. The value of microspheres is that they can be formulated for enhanced absorption or taste isolation. In addition, the microspheres may be formulated for controlled release, fast/slow release, pulsatile or timed release covering the full range of oral drug delivery requirements.

Microspheres created by Ceform technology.

Novopharm Limited specializes in the development and manufacture of generic and OTC pharmaceuticals with a subsidiary focused on treatments of cancer and HIV.

Fuisz Technologies Ltd. is engaged in the development, manufacture and commercialization of a wide range of drug delivery, nutraceutical and food ingredient products.

For more information: Kenneth W. McVey, Fuisz Technologies Ltd. Tel: 703-995-2400